135 related articles for article (PubMed ID: 36801480)
1. Bone targeted miRNA delivery system for miR-34a with enhanced anti-tumor efficacy to bone-associated metastatic breast cancer.
Han TY; Hou LS; Li JX; Huan ML; Zhou SY; Zhang BL
Int J Pharm; 2023 Mar; 635():122755. PubMed ID: 36801480
[TBL] [Abstract][Full Text] [Related]
2. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.
Gaur S; Wen Y; Song JH; Parikh NU; Mangala LS; Blessing AM; Ivan C; Wu SY; Varkaris A; Shi Y; Lopez-Berestein G; Frigo DE; Sood AK; Gallick GE
Oncotarget; 2015 Oct; 6(30):29161-77. PubMed ID: 26313360
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
4. In bone metastasis miR-34a-5p absence inversely correlates with Met expression, while Met oncogene is unaffected by miR-34a-5p in non-metastatic and metastatic breast carcinomas.
Maroni P; Puglisi R; Mattia G; Carè A; Matteucci E; Bendinelli P; Desiderio MA
Carcinogenesis; 2017 May; 38(5):492-503. PubMed ID: 28334277
[TBL] [Abstract][Full Text] [Related]
5. Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396800
[TBL] [Abstract][Full Text] [Related]
6. Polymer-Initiating Caveolae-Mediated Endocytosis and GSH-Responsive MiR-34a Gene Delivery System for Enhanced Orthotopic Triple Negative Breast Cancer Therapy.
Han TY; Huan ML; Cai Z; He W; Zhou SY; Zhang BL
Adv Healthc Mater; 2023 Dec; 12(32):e2302094. PubMed ID: 37827986
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly.
Lin X; Chen W; Wei F; Zhou BP; Hung MC; Xie X
Theranostics; 2017; 7(19):4805-4824. PubMed ID: 29187905
[No Abstract] [Full Text] [Related]
8. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
9. Effect of Tumor Suppressor MiR-34a Loaded on ZSM-5 Nanozeolite in Hepatocellular Carcinoma: In Vitro and In Vivo Approach.
Salah Z; Abd El Azeem EM; Youssef HF; Gamal-Eldeen AM; Farrag AR; El-Meliegy E; Soliman B; Elhefnawi M
Curr Gene Ther; 2019; 19(5):342-354. PubMed ID: 31701846
[TBL] [Abstract][Full Text] [Related]
10. Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.
Li G; Yao L; Zhang J; Li X; Dang S; Zeng K; Zhou Y; Gao F
Tumour Biol; 2016 Jun; 37(6):7481-91. PubMed ID: 26678891
[TBL] [Abstract][Full Text] [Related]
11. Cytosolic co-delivery of miRNA-34a and docetaxel with core-shell nanocarriers via caveolae-mediated pathway for the treatment of metastatic breast cancer.
Zhang L; Yang X; Lv Y; Xin X; Qin C; Han X; Yang L; He W; Yin L
Sci Rep; 2017 Apr; 7():46186. PubMed ID: 28383524
[TBL] [Abstract][Full Text] [Related]
12. The RNA-binding protein SART3 promotes miR-34a biogenesis and G
Sherman EJ; Mitchell DC; Garner AL
J Biol Chem; 2019 Nov; 294(46):17188-17196. PubMed ID: 31619517
[TBL] [Abstract][Full Text] [Related]
13. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.
Li L; Yuan L; Luo J; Gao J; Guo J; Xie X
Clin Exp Med; 2013 May; 13(2):109-17. PubMed ID: 22623155
[TBL] [Abstract][Full Text] [Related]
14. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.
Saini S; Majid S; Yamamura S; Tabatabai L; Suh SO; Shahryari V; Chen Y; Deng G; Tanaka Y; Dahiya R
Clin Cancer Res; 2011 Aug; 17(16):5287-98. PubMed ID: 21159887
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer.
Injinari N; Amini-Farsani Z; Yadollahi-Farsani M; Teimori H
Life Sci; 2021 Mar; 269():119027. PubMed ID: 33453248
[TBL] [Abstract][Full Text] [Related]
16. Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.
Taipaleenmäki H; Browne G; Akech J; Zustin J; van Wijnen AJ; Stein JL; Hesse E; Stein GS; Lian JB
Cancer Res; 2015 Apr; 75(7):1433-44. PubMed ID: 25634212
[TBL] [Abstract][Full Text] [Related]
17. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
Mackiewicz M; Huppi K; Pitt JJ; Dorsey TH; Ambs S; Caplen NJ
Breast Cancer Res Treat; 2011 Nov; 130(2):663-79. PubMed ID: 21814748
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1.
Yang S; Li Y; Gao J; Zhang T; Li S; Luo A; Chen H; Ding F; Wang X; Liu Z
Oncogene; 2013 Sep; 32(36):4294-303. PubMed ID: 23001043
[TBL] [Abstract][Full Text] [Related]
19. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy.
Wang S; Cao M; Deng X; Xiao X; Yin Z; Hu Q; Zhou Z; Zhang F; Zhang R; Wu Y; Sheng W; Zeng Y
Adv Healthc Mater; 2015 Jan; 4(2):281-90. PubMed ID: 25044638
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts.
Xu J; Zhang G; Luo X; Wang D; Zhou W; Zhang Y; Zhang W; Chen J; Meng Q; Chen E; Chen H; Song Z
Theranostics; 2021; 11(5):2475-2489. PubMed ID: 33500737
[No Abstract] [Full Text] [Related]
[Next] [New Search]
